Push­ing for top spot in Big Phar­ma, Ab­b­Vie lands a key ap­proval for its block­buster Skyrizi

Ab­b­Vie just scored an­oth­er win in its cam­paign to make Skyrizi one of the top block­busters in the port­fo­lio while push­ing the Big Phar­ma to the top of the in­dus­try list of mon­ey mak­ers as their cash cow Hu­mi­ra faces biosim­i­lar com­pe­ti­tion in Jan­u­ary.

Ear­li­er this year the FDA’s OK came through on pso­ri­at­ic arthri­tis, fol­low­ing the maid­en ap­proval for pso­ri­a­sis. And to­day we learned that the agency has stamped its ap­proval to ex­pand the la­bel to in­clude Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER